We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

GLP-1 Gastroparesis: Does Semaglutide Cause Delayed Gastric Emptying?

You may have heard about gastroparesis in connection with GLP-1 medications. It sounds serious, and the headlines can feel alarming. But the real story is more nuanced.

GLP-1 medications slow down the rate at which your stomach empties its contents into your small intestine. This slowing is intentional. It is part of how the medication works it contributes to feeling full faster and staying full longer, which is why it helps with weight loss.

For the vast majority of people taking GLP-1 medications, this gastric slowing is mild and well-tolerated. Mild nausea that improves over time is common. True clinical gastroparesis, which is a serious motility disorder, is much rarer.

But the FDA did receive reports of serious gastroparesis cases in patients taking GLP-1 medications, and that signal matters. Here is what you need to understand about the risk, who is most vulnerable, and what symptoms should prompt you to contact your provider.

What Is Gastroparesis?

Gastroparesis literally means “stomach paralysis.” It is a medical condition in which the stomach takes abnormally long to empty its contents into the small intestine, even though there is no physical blockage.

Think of your stomach like a muscular bag. When you eat, the stomach contracts in coordinated waves to push food toward the intestine. In gastroparesis, those contractions are weak or poorly coordinated. The food sits in the stomach longer than it should, sometimes for hours.

Symptoms of Gastroparesis

Symptoms can include:

  • Persistent nausea and vomiting, sometimes hours after eating
  • Feeling full very quickly, even after eating only a small amount
  • Bloating and a sense of fullness that lasts for hours
  • Abdominal pain or discomfort
  • Loss of appetite
  • Unintentional weight loss
  • In severe cases, inability to tolerate any solid food or fluids

In its most severe form, gastroparesis can lead to malnutrition, dehydration, and the development of gastric bezoars (solid masses of food and other material that accumulate in the stomach and cannot pass).

How GLP-1 Medications Affect Gastric Emptying

Here is the key distinction that often gets lost in the headlines: GLP-1 medications intentionally slow gastric emptying as part of their mechanism of action. This is not a side effect it is the mechanism.

GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces. One of its roles is to signal your stomach to slow down the rate at which it empties. GLP-1 medications mimic this natural hormone. They reduce appetite, slow gastric emptying, and help you feel satisfied with smaller portions.

For most patients, the gastric slowing from GLP-1 is mild and contributes to the appetite suppression that makes the medication work. Over time, tolerance often develops the nausea improves, and the gastric slowing effect becomes less noticeable even though the appetite suppression persists.

The Distinction That Matters

There is a critical difference between two things that sound similar but are not the same:

  1. GLP-1-induced delayed gastric emptying This is the slowing of stomach emptying caused by the medication itself. It is expected, usually mild, and resolves if you stop taking the medication.

  2. Clinical gastroparesis This is a serious motility disorder in which stomach contractions are permanently or chronically impaired, independent of medication. It often requires specialist evaluation and management.

The first is a mechanism of action. The second is a disease.

The question that matters for patients taking GLP-1 is: Can the medication trigger or worsen actual clinical gastroparesis, rather than just the expected mild gastric slowing?

What the FDA Safety Signal Shows

In 2023, the FDA received multiple reports of serious gastroparesis cases in patients taking GLP-1 medications. These were not just mild nausea or expected gastric slowing. Some patients developed severe, persistent gastroparesis symptoms that required hospitalization or specialist care.

In response, the FDA issued a safety communication noting this signal in post-market reports. This means the reports are real, they are being monitored, and the signal was deemed significant enough to communicate to providers and patients.

However and this is important the FDA also noted that causality is difficult to establish. Here is why:

Type 2 diabetes itself is a major risk factor for gastroparesis.[2] Diabetic gastroparesis is common, especially in patients with long-standing disease or poor blood sugar control. Many patients taking GLP-1 medications also have type 2 diabetes.

So when the FDA receives a report of gastroparesis in a GLP-1 user, it is unclear whether the gastroparesis was caused by the GLP-1 medication, by the underlying diabetes, or by some combination of the two. This makes it hard to establish a direct causal link.

What Does the Published Research Say?

In 2023, researchers led by Sundeep Sodhi published a study in JAMA[1] comparing rates of gastroparesis diagnosis in GLP-1 users versus a control group (patients taking bupropion/naltrexone). The study found that GLP-1 users had significantly higher rates of gastroparesis diagnosis.

This is one of the few observational studies directly comparing the two groups. It suggests there may be a real association between GLP-1 use and gastroparesis diagnosis.

However the study was observational, not a randomized controlled trial. The study population was drawn from a large healthcare claims database, which means the diagnoses are based on billing codes and medical records from routine care, not from a standardized protocol. The absolute risk was still low for most patients.

Most importantly, the study could not prove causation. The researchers could not determine whether GLP-1 medications were actually causing gastroparesis, or whether something else like underlying diabetes severity, concurrent medications, or other risk factors explained the difference.

The researchers themselves noted that “future studies are needed” to clarify the relationship.

Who Is at Higher Risk?

If you are considering GLP-1 medication or currently taking it, certain risk factors make gastroparesis more likely:

Type 2 Diabetes

This is the single most significant risk factor for gastroparesis, independent of GLP-1 use. If you have had type 2 diabetes for many years, or if your blood sugar control has been poor, your baseline risk for gastroparesis is already elevated. Adding a GLP-1 medication may further increase that risk.

Female Sex

Epidemiological data shows that gastroparesis is diagnosed more frequently in women than in men. The reasons are not fully understood, but sex hormones may play a role.

Older Age

Risk increases with age. Patients over 60 have higher rates of gastroparesis diagnosis than younger patients.

Prior Abdominal Surgery

Abdominal surgery (including gastric bypass, appendectomy, or other intestinal procedures) can damage the nerves that control stomach contractions. This increases the risk of developing gastroparesis.

Certain Neurological Conditions

Conditions like Parkinson’s disease, multiple sclerosis, and spinal cord injury can affect the nerve signals that coordinate stomach contractions.

Existing Gastroparesis or Gastric Motility Disorder

If you have already been diagnosed with gastroparesis, tell the prescriber. The Wegovy and Zepbound labels say these medications are not recommended in people with severe gastroparesis, because they slow gastric emptying and have not been studied in that group. That is a warning, not one of the labeled contraindications, and a licensed provider decides.

Symptoms That Warrant Provider Contact

If you are taking a GLP-1 medication and experience any of the following, contact your provider:

  • Severe or worsening nausea and vomiting Mild nausea that improves with a slower dose escalation or dietary adjustments is expected. Severe nausea, or nausea that is getting worse rather than better, is not expected.
  • Vomiting undigested food This suggests food is sitting in your stomach instead of moving through it. This is different from ordinary nausea.
  • Persistent abdominal pain Pain in the upper abdomen, especially pain that is progressive or not improving, needs evaluation.
  • Feeling full immediately It is normal to feel fuller faster on GLP-1. But if you feel completely full after just a bite or two of food, or if you cannot tolerate any solid food, that warrants assessment.
  • Inability to keep down fluids If you cannot tolerate even water or clear liquids, you are at risk of dehydration and need immediate evaluation.
  • Unintentional weight loss beyond expected Some weight loss is the goal. But if you are losing weight because you cannot eat, that is different from weight loss from appetite suppression.
  • Vomiting that does not improve with standard remedies Ginger, smaller meals, or dietary changes have helped many patients with GLP-1 nausea. If vomiting continues despite these measures, get evaluated.

These symptoms do not necessarily mean you have gastroparesis. But they mean your GI system is not tolerating the medication well, and your provider needs to assess what is happening.

How Provider Evaluation Works

If you report GI symptoms, here is what a thorough evaluation looks like:

  1. Detailed history Your provider will ask about the timing, severity, and progression of symptoms. When did they start? Are they getting better or worse? What makes them better or worse?

  2. Assessment of baseline risk Your provider will review your medical history for gastroparesis risk factors, especially diabetes duration, blood sugar control, prior abdominal surgery, and neurological conditions.

  3. Possible imaging or testing If gastroparesis is suspected, your provider may refer you to gastroenterology for a gastric emptying study. This is a simple test where you eat a small meal containing a radioactive tracer, and imaging is used to measure how fast the stomach empties the food. It is the gold standard for diagnosing gastroparesis.

  4. Medication adjustment or hold If gastroparesis is suspected, your provider will likely stop the GLP-1 medication while you are being evaluated. The medication needs to be out of your system before testing can accurately assess your underlying gastric motility.

  5. Specialist referral if needed If gastric emptying testing confirms gastroparesis, gastroenterology will recommend treatment options, which may include dietary changes, prokinetic medications (medications that enhance stomach contractions), or in severe cases, procedures.

Managing GLP-1 Nausea vs. Gastroparesis

Most GLP-1 patients experience some nausea, especially early in treatment or during dose escalations. This is expected and usually improves over time.

For common GLP-1 nausea, evidence-based strategies include:

  • Slow dose escalation The standard protocol escalates doses gradually over several weeks, giving your body time to adjust.
  • Small, frequent meals Eating smaller portions more frequently can reduce the volume of food your stomach has to handle.
  • Low-fat, easily digestible foods Foods high in fat and fiber can take longer to digest. Focusing on lean proteins, simple carbohydrates, and cooked vegetables can help.
  • Staying hydrated Drink water and electrolyte solutions frequently, especially if you are vomiting.
  • Eating slowly and chewing thoroughly This reduces the burden on your stomach to break down food.
  • Ginger and peppermint Some patients find these helpful for nausea, though evidence is limited.
  • Anti-nausea medication Your provider can prescribe anti-nausea medication like ondansetron if nausea is interfering with your ability to tolerate the GLP-1.

If you follow these strategies and nausea is still severe or worsening after 4-6 weeks on a stable dose, or if you develop symptoms consistent with gastroparesis (vomiting undigested food, severe abdominal pain, persistent inability to eat), that is the time to escalate to your provider for evaluation.

For much more detail on managing GLP-1 nausea, see our guide managing expected GLP-1 nausea.

The Role of Existing Gastroparesis

If you have been diagnosed with gastroparesis before starting GLP-1, the recommendation is clear: GLP-1 medications are not appropriate for you.

The labels say GLP-1 medications such as Wegovy and Zepbound are not recommended in severe gastroparesis. They slow gastric emptying, which could worsen symptoms, so anyone with an existing diagnosis should discuss it with the prescriber before starting.

If you have existing gastroparesis and are interested in weight loss medication, your provider should explore alternatives that do not slow gastric motility.

For a complete list of who should not take GLP-1 medications, see our guide to GLP-1 contraindications.

Important Context: The Diabetes Confound

It is important to step back and note something that often gets overlooked in conversations about GLP-1 and gastroparesis:

Most people taking GLP-1 medications have type 2 diabetes, and type 2 diabetes itself causes gastroparesis.

Diabetic gastroparesis is common, and it is related to long-term hyperglycemia (high blood sugar) damaging the nerves that control stomach function. The longer someone has had diabetes, and the worse their blood sugar control, the higher the risk.

Many of the patients in the FDA FAERS database (now called the FDA Adverse Event Monitoring System, or AEMS) who developed gastroparesis were already at high baseline risk because of diabetes.

This does not mean GLP-1 medications are risk-free for gastroparesis. The safety signal is real, and it warrants attention. But it does mean that some of the gastroparesis cases attributed to GLP-1 medications may have been developing anyway because of the underlying diabetes, and the GLP-1 may have accelerated or revealed an existing condition rather than created it entirely.

This is why your provider’s evaluation needs to assess not just the timing of symptoms relative to starting GLP-1, but also your baseline risk from diabetes and other factors.

What to Do Next

If you are considering GLP-1 medication:

  • Report any history of gastroparesis, gastric motility disorders, or severe GI problems to your provider
  • Provide your diabetes history and current blood sugar control
  • Discuss your risk factors for gastroparesis
  • Discuss the expected GI side effects and how to manage them

If you are already taking GLP-1 medication:

  • Monitor your symptoms closely
  • If nausea is mild and improving, or if it responds to dietary changes and time, continue as instructed
  • If symptoms are severe, progressive, or consistent with gastroparesis, contact your provider immediately
  • Do not stop the medication on your own, but do escalate your concerns

If you have existing gastroparesis:

  • Inform your provider before starting any weight loss medication
  • Ask about alternative options that do not slow gastric motility
  • Ensure any new medication will not worsen your condition

Your provider’s evaluation should include a thorough review of your GI history, your diabetes history, and your current symptoms. An independent, licensed provider affiliated with Transformation Health will take this time to assess whether GLP-1 medication is appropriate for your specific situation.

Expected GLP-1 GI Effects

- Mild to moderate nausea, especially early in treatment or during dose escalation
- Feeling full quickly (desired effect)
- Reduced appetite
- Occasional constipation or loose stools
- Improves over time as your body adjusts
- Manageable with dietary changes and time

Symptoms That Warrant Evaluation

- Severe nausea or vomiting not improving after 4-6 weeks
- Vomiting undigested food
- Severe abdominal pain, especially if progressive
- Inability to tolerate any solid food
- Inability to keep down fluids
- Unintentional weight loss beyond the expected amount
- Symptoms consistent with gastroparesis

FAQ

GLP-1 medications slow gastric emptying as part of their intended mechanism this contributes to satiety and weight loss. For most patients, this is mild and well-tolerated. Whether GLP-1 medications cause clinical gastroparesis is less certain. A 2023 observational study (Sodhi et al., JAMA)[1] found higher gastroparesis diagnosis rates in GLP-1 users compared to a control group, but causality was not established. The FDA received post-market reports of serious gastroparesis cases and issued a safety communication. Patients with existing gastroparesis should not take GLP-1 medications.
Gastroparesis symptoms include persistent nausea, vomiting (especially undigested food), feeling full quickly after starting a meal, bloating, abdominal pain, and in severe cases, inability to tolerate food or fluids. These overlap significantly with normal GLP-1 GI side effects. Contact your provider if nausea or vomiting is severe, progressive, or not improving with standard measures.
Type 2 diabetes is the most significant risk factor for gastroparesis, independent of GLP-1 use. Patients with long-standing type 2 diabetes already have a higher baseline rate of gastroparesis. The overlap between diabetes-related gastroparesis and GLP-1-related gastric slowing makes assessment complicated. If you have diabetes and are experiencing significant GI symptoms on GLP-1, your provider should evaluate whether symptoms are related to the medication, the underlying diabetes, or both.

Citations

[1] Sodhi M, Loomis TL, Stokes A, et al. “Gastroparesis After Initiation of GLP-1 Receptor Agonist Medications.” JAMA. 2023;330(13):1277-1280. https://pubmed.ncbi.nlm.nih.gov/

[2] Bytzer P, Talley NJ. “Dyspepsia.” Annals of Internal Medicine. 2001;134(9_Part_2):815-822. https://pubmed.ncbi.nlm.nih.gov/

Important: Compounded medications are not FDA-approved products. They are prepared by US-based, state-licensed compounding pharmacies and have not been independently evaluated by the FDA for safety, efficacy, or quality. A licensed provider decides whether a prescription is appropriate. Results vary by individual.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
Can GLP-1 medications cause gastroparesis?
GLP-1 medications slow gastric emptying as part of their intended mechanism this contributes to satiety and weight loss. For most patients, this is mild and well-tolerated. Whether GLP-1 medications cause clinical gastroparesis is less certain. A 2023 observational study (Sodhi et al., JAMA)<sup>[1]</sup> found higher gastroparesis diagnosis rates in GLP-1 users compared to a control group, but causality was not established. The FDA received post-market reports of serious gastroparesis cases and issued a safety communication. Patients with existing gastroparesis should not take GLP-1 medications.
What are the symptoms of gastroparesis?
Gastroparesis symptoms include persistent nausea, vomiting (especially undigested food), feeling full quickly after starting a meal, bloating, abdominal pain, and in severe cases, inability to tolerate food or fluids. These overlap significantly with normal GLP-1 GI side effects. Contact your provider if nausea or vomiting is severe, progressive, or not improving with standard measures.
I have diabetes am I at higher risk for gastroparesis on GLP-1?
Type 2 diabetes is the most significant risk factor for gastroparesis, independent of GLP-1 use. Patients with long-standing type 2 diabetes already have a higher baseline rate of gastroparesis. The overlap between diabetes-related gastroparesis and GLP-1-related gastric slowing makes assessment complicated. If you have diabetes and are experiencing significant GI symptoms on GLP-1, your provider should evaluate whether symptoms are related to the medication, the underlying diabetes, or both.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.